FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
-9.86%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$234M
AUM Growth
+$234M
(-25%)
Cap. Flow
+$4.71M
Cap. Flow
% of AUM
2.01%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$4.71M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $59M | 25.2% |
9,671,643
| – | – |
|
2
Aclaris Therapeutics
ACRS
$220M
| $44.2M | 18.89% |
2,808,034
| – | – |
|
3
Pharvaris
PHVS
$1.43B
| $36.5M | 15.6% |
3,246,926
| – | – |
|
4
Lyell Immunopharma
LYEL
$220M
| $34.7M | 14.82% |
10,000,000
| – | – |
|
5
Kura Oncology
KURA
$726M
| $23M | 9.81% |
1,849,947
| – | – |
|
|
6
Syndax Pharmaceuticals
SNDX
$1.37B
| $22.3M | 9.51% |
875,000
+185,000
| +27% | +$4.71M |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $11.2M | 4.79% |
1,787,094
| – | – |
|
8
Quantum-Si Incorporated
QSI
$213M
| $3.24M | 1.38% |
1,771,249
| – | – |
|